How to work with a medtech CRO and stay in control

May 21, 2026 ░░░░░░

Most medtech manufacturers approach a clinical study the same way: find a contract research organization (CRO), hand over the protocol, and wait for data. The appeal is obvious. Clinical operations are complex, heavily regulated, and far outside the day-to-day work of a device company. Outsourcing feels like the rational solution.

The problem is that outsourcing execution does not transfer accountability. Under ISO 14155 (International Organization for Standardization 14155) and good clinical practice requirements, the sponsor remains liable for everything that happens in a study. The CRO works for you. You do not get to stop thinking about it once the contract is signed.

What I see repeatedly is manufacturers who lose control, not because they chose the wrong CRO, but because they did not have a clear model for what staying in control actually looks like. Here is how to think about it.

Start by knowing what you are and are not equipped to do

Before approaching any CRO, map your internal capabilities honestly. This is not about being embarrassed by gaps. It is about knowing where you genuinely need expertise and where you are giving up control unnecessarily.

Most small and mid-sized medtech companies can do more in-house than they assume. Protocol development, case report form design, and study report writing are often within reach if you have capable clinical and regulatory people. Monitoring, on the other hand, gets expensive and logistically difficult the moment your study goes multicountry. A CRO with established site networks and local monitors is genuinely more efficient than trying to staff that function yourself across multiple geographies.

The functions most commonly outsourced are electronic data capture (EDC) setup, site monitoring, and biostatistics. Of these, EDC has shifted significantly in the last several years. It used to require specialized programming and data management expertise that most device companies did not have, which made outsourcing it the obvious move. Today, purpose-built medical device EDC systems like Greenlight Guru Clinical are designed so that manufacturer-side teams can build and manage their own study databases without technical overhead. That changes what you need to send to a CRO and what you can keep.

Biostatistics is the one area that remains genuinely specialized. Finding someone who understands both device study design and statistical methodology, and who can explain their reasoning clearly, is difficult even inside experienced CROs. Plan to outsource this unless you have it in-house.

The most important in-house capability, though, is not a technical function. Somebody at your company needs to understand vendor management and have enough clinical operations experience to manage the CRO relationship from the sponsor side. A CRO that defers every decision back to a sponsor who cannot evaluate the options is not being helpful. You need someone internal who can push back, ask the right questions, and recognize when something is going wrong before it becomes expensive.

How to find and select the right CRO

The medtech CRO market looks nothing like the pharma CRO market. The large generalist firms are built for pharmaceutical research. Some have medtech units, either organically built or acquired, but medtech is not their primary business. For most device manufacturers, a purpose-built medtech CRO is a better fit.

These organizations tend to be smaller, more specialized, and often focused on specific therapeutic areas or device types. A CRO that runs exclusively medical device studies in ophthalmology or cardiology brings a depth of site relationships, regulatory familiarity, and procedural knowledge that a generalist firm cannot match. The tradeoff is scale: a boutique CRO may not have the bandwidth for a very large study or the geographic footprint for complex multicountry work. Most medtech studies are not that large.

A concrete starting point for building your shortlist is our top 40+ medtech CRO list. From there, direct conversations are a faster filter than formal tenders. Reach out to ten, have half-hour introductory calls, and identify the three or four worth asking for a detailed quote.

When you are evaluating them, five things matter most: device experience, size and fit, indication experience, realism, and communication style. Device experience first. ISO 14155 familiarity is baseline. Ask specifically. If the answer is vague, that tells you what you need to know. Size and fit next. A CRO that is similar to your company in size, or smaller, tends to be more responsive and more willing to engage as a genuine partner. Realism: a good CRO will challenge what is unrealistic in your brief. Communication style: what you are looking for is a team that will tell you proactively when something is going sideways rather than waiting for you to ask.

Before you sign, understand the contract

The master service agreement and the statement of work are your primary protections when something goes wrong. Make agreements upfront on how issues will be escalated and who owns each category of decision. Exit clauses are worth reading carefully. On budget structure: fully fixed-price contracts are rare in clinical research. The standard model is time-and-materials with a budget cap, with change orders when scope shifts. Monitoring represents roughly 40 percent of total study cost in many medtech trials, and managing budgets in clinical investigations is harder than most manufacturers anticipate going in.

Site selection and enrollment are where most studies fail

Sites overestimate their enrollment capacity. This is structural. Your CRO should apply the same rigor to enrollment forecasting as you would to calculating your sample size. The two things that most reliably derisk site performance are thorough qualification visits and realistic enrollment projections. Starting with fewer, better-qualified sites is usually a stronger strategy than covering risk by adding sites upfront. Protocol deviations that lead to patient exclusions are the third common cause of cost overruns.

Manage the ongoing relationship actively

Meeting structure is one of the biggest drivers of CRO cost overruns. Establish a single point of contact on each side and keep larger group calls to genuinely necessary milestones. One role worth keeping in-house is medical writing. The sponsor who writes their own report is the sponsor who understands their own data.

The CRO you choose the second time is usually right

The first study with a new CRO is, in practice, a test. That is why experienced clinical teams rarely switch CROs once they find one that works. A CRO you trust is worth the premium. Keep the study design clean, the site count manageable, and the meeting structure lean.

Keep reading

If you are planning a medtech clinical study or evaluating your outsourcing model, these guides go deeper on the specific components:

Our on-demand webinar on working with medtech CROs covers the full conversation in depth. For more on EDC and clinical data management, the clinical data management guide for medtech covers what manufacturers need to know. To see how Greenlight Guru Clinical supports study teams, get a demo of Greenlight Guru Clinical.